Ancora Heart Raises $80M To Support Ongoing Trial To Treat Heart Failure Patients
Executive Summary
Ancora Heart will use the new funding to accelerate its pivotal trial of the AccuCinch ventricular restoration system for treating heart failure patients with reduced ejection fraction.
You may also be interested in...
CVRx Raises $75M In IPO To Commercialize And Develop Heart Failure Therapy
The funds will support expanded commercialization of the company’s baroreflex activation stimulation technology to treat heart failure in patients with a low left-ventricular ejection fraction.
Minute Insight: Smith + Nephew Expands VR-based Surgical Training
Smith + Nephew is expanding its suite of simulation technologies to train surgeons on new techniques before they enter the operating room.
BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.